Idun Pharmaceuticals Announces Partnership Extension With Abbott Laboratories

- Successful Collaboration to Develop Cancer Therapies Extended to 4th Year -



Apr 18, 2001, 01:00 ET from Idun Pharmaceuticals, Inc.

    SAN DIEGO, April 18 /PRNewswire/ -- Idun Pharmaceuticals, Inc. today
 announced the extension of their worldwide research and development agreement
 with Abbott Laboratories focusing on the discovery and development of products
 to treat people with cancer.
     Under this agreement, Abbott and Idun will continue their collaboration to
 discover drugs that regulate the activity of specific proteins involved in the
 cell pathways leading to programmed cell death, or apoptosis.  This strategic
 initiative combines proprietary technologies from both Abbott and Idun in a
 major discovery effort to identify small molecule drugs that kill tumor cells
 by specifically targeting the apoptosis pathway.
     Under the original collaboration, which began in 1998, Idun developed
 primary molecular assays against targets in the core of the apoptosis pathway.
 Abbott uses these assays for high-throughput screening of compound libraries
 and for compound design using Abbott's proprietary Structure Activity
 Relationships by Nuclear Magnetic Resonance (SAR by NMR) technology.
 Secondary screening is carried out by Idun using its battery of proprietary
 biological apoptosis assays.
     SAR by NMR was developed at Abbott and uses nuclear magnetic resonance
 spectroscopy to screen a defined library of diverse small molecules for their
 ability to bind to the individual pockets of a protein drug target.  This
 technique has been shown to significantly reduce the amount of time involved
 in identifying molecules that bind to important protein drug targets, a key
 step in drug development.
     "During the past three years we have made significant progress in the
 discovery of innovative treatments for cancer through our partnership with
 Abbott Laboratories," says Dr. Steven J. Mento, President and CEO, Idun
 Pharmaceuticals.  "One of the key targets for development in this program has
 been compounds that inhibit the Bcl-2 family of anti-apoptotic proteins, which
 are proteins that allow cancer cells to survive under conditions that would
 trigger cell death in normal cells.  Our work in this area is focused on
 understanding how we can affect cell death in these types of cancer cells."
     "The collaborative program between Abbott and Idun for cancer research has
 been successful to date and we are pleased to be able to extend our
 collaboration with Idun," says Steve Fesik, Ph.D., Divisional Vice President,
 Cancer Research at Abbott Laboratories.  "Abbott is committed to the discovery
 and development of innovative treatments for cancer that will provide hope for
 the patients who are affected by this deadly disease."
 
     Idun Pharmaceuticals, Inc. is a biopharmaceutical company based in San
 Diego, Calif.  It creates innovative human therapeutics with a primary focus
 on controlling apoptosis, or programmed cell death.  Idun believes that
 controlling the cell death process will have utility in treating cancer,
 neurodegenerative diseases, ischemic disorders and cardiovascular disease.
 The company has adopted a commercialization strategy encompassing strategic
 collaborations with major pharmaceutical companies, internal, independent
 development of selected small molecule therapeutics, and out-licensing of
 diagnostics, gene therapies, and bioproduction technologies.  Idun has a broad
 patent portfolio covering the fundamental and core technologies involved in
 the regulation of cell death and has established partnerships in research
 reagents.
 
     Contact:
     Idun Pharmaceuticals
     Steven J. Mento, Ph.D.
     President and CEO
     (858) 623-1330
     http://www.idun.com
 
     Noonan/Russo Communications, Inc.
     Andi Wakayama (Media)
     (415) 677-4455, ext. 252
     http://www.noonanrusso.com
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X86366294
 
 

SOURCE Idun Pharmaceuticals, Inc.
    SAN DIEGO, April 18 /PRNewswire/ -- Idun Pharmaceuticals, Inc. today
 announced the extension of their worldwide research and development agreement
 with Abbott Laboratories focusing on the discovery and development of products
 to treat people with cancer.
     Under this agreement, Abbott and Idun will continue their collaboration to
 discover drugs that regulate the activity of specific proteins involved in the
 cell pathways leading to programmed cell death, or apoptosis.  This strategic
 initiative combines proprietary technologies from both Abbott and Idun in a
 major discovery effort to identify small molecule drugs that kill tumor cells
 by specifically targeting the apoptosis pathway.
     Under the original collaboration, which began in 1998, Idun developed
 primary molecular assays against targets in the core of the apoptosis pathway.
 Abbott uses these assays for high-throughput screening of compound libraries
 and for compound design using Abbott's proprietary Structure Activity
 Relationships by Nuclear Magnetic Resonance (SAR by NMR) technology.
 Secondary screening is carried out by Idun using its battery of proprietary
 biological apoptosis assays.
     SAR by NMR was developed at Abbott and uses nuclear magnetic resonance
 spectroscopy to screen a defined library of diverse small molecules for their
 ability to bind to the individual pockets of a protein drug target.  This
 technique has been shown to significantly reduce the amount of time involved
 in identifying molecules that bind to important protein drug targets, a key
 step in drug development.
     "During the past three years we have made significant progress in the
 discovery of innovative treatments for cancer through our partnership with
 Abbott Laboratories," says Dr. Steven J. Mento, President and CEO, Idun
 Pharmaceuticals.  "One of the key targets for development in this program has
 been compounds that inhibit the Bcl-2 family of anti-apoptotic proteins, which
 are proteins that allow cancer cells to survive under conditions that would
 trigger cell death in normal cells.  Our work in this area is focused on
 understanding how we can affect cell death in these types of cancer cells."
     "The collaborative program between Abbott and Idun for cancer research has
 been successful to date and we are pleased to be able to extend our
 collaboration with Idun," says Steve Fesik, Ph.D., Divisional Vice President,
 Cancer Research at Abbott Laboratories.  "Abbott is committed to the discovery
 and development of innovative treatments for cancer that will provide hope for
 the patients who are affected by this deadly disease."
 
     Idun Pharmaceuticals, Inc. is a biopharmaceutical company based in San
 Diego, Calif.  It creates innovative human therapeutics with a primary focus
 on controlling apoptosis, or programmed cell death.  Idun believes that
 controlling the cell death process will have utility in treating cancer,
 neurodegenerative diseases, ischemic disorders and cardiovascular disease.
 The company has adopted a commercialization strategy encompassing strategic
 collaborations with major pharmaceutical companies, internal, independent
 development of selected small molecule therapeutics, and out-licensing of
 diagnostics, gene therapies, and bioproduction technologies.  Idun has a broad
 patent portfolio covering the fundamental and core technologies involved in
 the regulation of cell death and has established partnerships in research
 reagents.
 
     Contact:
     Idun Pharmaceuticals
     Steven J. Mento, Ph.D.
     President and CEO
     (858) 623-1330
     http://www.idun.com
 
     Noonan/Russo Communications, Inc.
     Andi Wakayama (Media)
     (415) 677-4455, ext. 252
     http://www.noonanrusso.com
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X86366294
 
 SOURCE  Idun Pharmaceuticals, Inc.